In patients with early Alzheimer’s disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.
Donanemab, an investigational antibody that targets a modified form of beta amyloid, showed significant slowing of decline in cognition and daily function.
Alzheimer’s disease and related dementias were associated with adverse financial events starting years prior to clinical diagnosis.
The Clinical Research Center staff presented their findings at the 13th Clinical Trials on Alzheimer’s Disease Conference.
Dr. Weisman discusses COVID-19, Alzheimer’s disease, and clinical research with Jerry Rothkoff.
Thanks to the latest research, we can now target specific migraine pathways.
Infusion therapy may seem modern, but its origins trace as far back as 1492.
Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.
Your health is our top priority and we want to ensure that you are accessing — and not delaying — the care you need.
In many ways we’ve been fortunate. Despite a pandemic, society has not broken down.
